ClinicalTrials.gg
RecruitingNCT06613360Updated Oct 26, 2026

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

A Phase 1 interventional study of CLN-978 in SLE and SLE (Systemic Lupus), sponsored by Cullinan Therapeutics Inc.. Recruiting at 24 sites in 9 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Cullinan Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 22, 2026First sites in Germany and SpainSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Planned enrollment
304th of 407
24 · median 70
Started
2025
with 29 others
Phase 1
104 of 477
24 open now
Primary completion
2026-12
later than 21 of 125 live
Registered
419th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 304th largest by planned enrollment of the 407 interventional ones that give a count, is one of 30 that started in 2025, is one of 104 in phase 1, reaches primary completion later than 21 of the 125 other live ones, and was the 419th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

03

Conditions studied

  • SLE
  • SLE (Systemic Lupus)

Keywords

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SLE at least 24 weeks prior to Screening and meet 2019 EULAR / ACR Classification Criteria at screening.
  • Presence of one or more of the following autoantibodies documented during screening or in the previous 12 months before screening: positive anti-nuclear antibody (ANA) test (≥1:80); anti dsDNA above the (ULN); anti-Sm above the ULN.
  • Active SLE disease, as demonstrated by a SLEDAI total score ≥6 at screening.
  • Inadequate response to at least 2 of the following treatments: oral , antimalarials, conventional , or biologics. At least one of the failed treatments should be an immunosuppressive or biologic standard-of care agent.
  • If on corticosteroid and/or antimalarial, the dose must be stable prior to day 1.
  • Laboratory parameters including the following:

    • Absolute lymphocyte count (ALC) ≥0.5 x 109/L
    • Peripheral B cell count ≥25 cells/µL
    • (ANC) ≥1.0 x 109/L
    • ≥8 g/dL
    • count ≥75 x 109/L.
    • Estimated (eGFR) (based on CKD-EPI formula) ≥30 mL/min/1.73m2
    • Total ≤1.5 × ULN, except patients with confirmed Gilbert's Syndrome
    • (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN
  • Part B only: For patients who were treated in Part A and did not experience dose-limiting toxicity (DLT) or discontinue CLN-978 treatment due to AEs are eligible for retreatment at a higher dose or longer schedule in Part B if they otherwise meet eligibility criteria and at least 90 days have passed since the last dose of CLN-978.

Exclusion criteria

Exclusion Criteria:

  • Active inflammatory disease other than SLE. Thyroiditis or secondary Sjogren's syndrome is allowed.
  • Considered at high risk for thrombosis.
  • Rapidly progressive glomerulonephritis, and/or urine protein/creatinine >3 mg/mg (339 mg/mmol).
  • Active severe neuropsychiatric/CNS manifestations of SLE.
  • Evidence of , (HCV) infection, (HIV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) infection.
  • History of splenectomy.
  • Prior treatment with the following:

    • Cellular or gene therapy product directed at any target.
    • therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to Day 1.
    • Any anti-CD19 or anti-CD20 therapy less than 3 months prior to Day 1.
    • Non-biologic DMARD within 14 days prior to Day 1.
    • Cyclophosphamide within 1 month or a biologic immunomodulating therapy during 2 months prior to Day 1.
  • Live or attenuated vaccine within 28 days prior to screening or during screening.
  • Active, bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including SARS-CoV-2 infection, within 14 days before Day 1.
  • Active or latent tuberculosis (TB) evidenced by a positive or indeterminant Interferon Gamma Release Assay (IGRA), unless the patient has documented previous completion of TB treatment and no current clinical indication of TB.
  • Any condition for which, in the opinion of the Investigator and/or Sponsor, would not be in the best interest of the patient to participate in the study or that could prevent, limit, or confound any protocol-defined assessment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Part A Dose Escalation

    Patients with SLE treated with CLN-978 in dose escalation cohorts

    Drug: CLN-978

  • Experimental
    Part B Further Dose Evaluation

    Further evaluation of CLN-978 treatment of patients with SLE

    Drug: CLN-978

Interventions

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs)

    Time frame: 48 weeks

Secondary outcomes

  1. Pharmacokinetics

    Serum concentrations of CLN-978

    Time frame: 48 weeks

  2. Immunogenicity

    Level of anti-drug antibodies

    Time frame: 48 weeks

  3. Pharmacodynamics-related biomarker

    Levels of total B lymphocytes in the peripheral blood

    Time frame: 48 weeks

Other outcomes

  1. hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI)

    Change in hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score on a scale of 0 to12 with a higher score meaning worse outcome

    Time frame: 48 weeks

  2. Physicians Global Assessment

    Change in Physicians Global Assessment (PGA) score on a scale of 0 to 3 with a higher score indicating worse outcome

    Time frame: 48 weeks

07

Study locations

22 of 24 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 23 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 25, 2024
StartActual
Jan 21, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first sites in Germany and Spain. Columbia University Medical Center is now Withdrawn
Show 4 added (2 United States, 1 Germany, 1 Spain)
  • Boston Children's Hospital · Boston, United States
  • NYU Grossman School of Medicine · New York, United States
  • Klinikum der Ruprecht-Karls Universitaet Heidelberg · Heidelberg, Germany
  • Hospital Quironsalud Infanta Luisa · Seville, Spain
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Stryde Research · Plano, United StatesContact a•••@stryderesearch.com · •••7721→m•••@stryderesearch.com · •••7558
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Stryde Research · Plano, United StatesContact a•••@stryderesearch.com · •••7721→m•••@stryderesearch.com · •••7558
  2. Oct 22, 2026
    4 sites added — first sites in Germany and Spain. Columbia University Medical Center is now Withdrawn
    Show 4 added (2 United States, 1 Germany, 1 Spain)
    • Boston Children's Hospital · Boston, United States
    • NYU Grossman School of Medicine · New York, United States
    • Klinikum der Ruprecht-Karls Universitaet Heidelberg · Heidelberg, Germany
    • Hospital Quironsalud Infanta Luisa · Seville, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06613360
Lead sponsor
Cullinan Therapeutics Inc.
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Jan 21, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Meagan Sardinha
Contact
ClinOps@cullinantx.com
+1 617 410 4650

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978

Start the discussion